BCR-ABL1 doubling-times and halving-times may predict CML response to tyrosine kinase inhibitors

Elena Tirrò, Sergio Siragusa, Sandra Di Gregorio, Elena Tirrò, Agostino Antolino, Donato Mannina, Valentina Zammit, Silvia Rita Vitale, Sergio Siragusa, Giuseppe Mineo, Adriana Puma, Fabio Stagno, Maria Stella Pennisi, Chiara Romano, Stefana Impera, Paolo Vigneri, Livia Manzella, Bruno Martino, Caterina Musolino, Michele MassiminoFrancesco Di Raimondo, Stefania Stella

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)

Abstract

In Chronic Myeloid Leukemia (CML), successful treatment requires accurate molecular monitoring to evaluate disease response and provide timely interventions for patients failing to achieve the desired outcomes. We wanted to determine whether measuring BCR-ABL1 mRNA doubling-times (DTs) could distinguish inconsequential rises in the oncogene’s expression from resistance to tyrosine kinase inhibitors (TKIs). Thus, we retrospectively examined BCR-ABL1 evolution in 305 chronic-phase CML patients receiving imatinib mesylate (IM) as a first line treatment. Patients were subdivided in two groups: those with a confirmed rise in BCR-ABL1 transcripts without MR3.0 loss and those failing IM. We found that the DTs of the former patients were significantly longer than those of patients developing IM resistance (57.80 vs. 41.45 days, p = 0.0114). Interestingly, the DT values of individuals failing second-generation (2G) TKIs after developing IM resistance were considerably shorter than those observed at the time of IM failure (27.20 vs. 41.45 days; p = 0.0035). We next wanted to establish if decreases in BCR-ABL1 transcripts would identify subjects likely to obtain deep molecular responses. We therefore analyzed the BCR-ABL1 halving-times (HTs) of a different cohort comprising 174 individuals receiving IM in first line and observed that, regardless of the time point selected for our analyses (6, 12, or 18 months), HTs were significantly shorter in subjects achieving superior molecular responses (p = 0.002 at 6 months; p < 0.001 at 12 months; p = 0.0099 at 18 months). Moreover, 50 patients receiving 2G TKIs as first line therapy and obtaining an MR3.0 (after 6 months; p = 0.003) or an MR4.0 (after 12 months; p = 0.019) displayed significantly shorter HTs than individuals lacking these molecular responses. Our findings suggest that BCR-ABL1 DTs and HTs are reliable tools to, respectively, identify subjects in MR3.0 that are failing their assigned TKI or to recognize patients likely to achieve deep molecular responses that should be considered for treatment discontinuation.
Original languageEnglish
Pages (from-to)764-
Number of pages9
JournalFrontiers in Oncology
Volume9
Publication statusPublished - 2019

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'BCR-ABL1 doubling-times and halving-times may predict CML response to tyrosine kinase inhibitors'. Together they form a unique fingerprint.

Cite this